Results 61 to 70 of about 23,315 (198)
Indian Journal of Endocrinology and Metabolism, 2014 Objectives: This retrospective cohort study analyzed the clinical data of cancer patients conducted in a cancer hospital, Chennai to assess the correlation (if any) between use of antidiabetic agents including pioglitazone and the incidence of bladder ...
V Balaji +4 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Lobeglitazone is a thiazolidinedione and PPARγ agonist that improves metabolic parameters and hepatic steatosis, but its mechanisms are not fully understood. This study investigated the effects of lobeglitazone on hepatic transcriptomic and metabolic profiles in a rat model of obesity and Type 2 diabetes mellitus.
Hyekyung Yang +6 more
wiley +1 more source
PLoS ONE, 2012 BackgroundEvidence suggests that the PPARγ-agonist insulin sensitizer pioglitazone, may provide potential beneficial cardiovascular (CV) effects beyond its anti-hyperglycaemic function.
Valentina Spigoni +9 more
doaj +1 more source
Rosiglitazone and Pioglitazone Alter Aromatase Kinetic Properties in Human Granulosa Cells
PPAR Research, 2011 We have previously reported that, in human granulosa cells, thiazolidinediones rosiglitazone and pioglitazone inhibit estrogen synthesis by interfering with androgen binding to aromatase, without an effect on aromatase mRNA or protein expression.
Takako Araki +5 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii +5 more
wiley +1 more source
Cellular Physiology and Biochemistry, 2016 Background/Aims: Pioglitazone is a type of peroxisome proliferator-activated receptor γ agonist and is capable of alleviating renal ischemia-reperfusion injury.
Li Sun +8 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu +6 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake +14 more
wiley +1 more source
Cost Effectiveness and Resource Allocation, 2009 Background The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk ...
Massi-Benedetti Massimo +5 more
doaj +1 more source